Sanja Vrbek (Author), Irena Mlinarič-Raščan (Author), Žiga Jakopin (Author)

Abstract

In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side%effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide%binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has already been approved in Europe by the European Medicine Agency for treating patients with osteosarcoma in combination with chemotherapy after complete surgical removal of the primary tumor. This review is focused on NOD receptors as promising targets in cancer immunotherapy as well as summarizing current knowledge of the various NOD ligands exhibiting antitumor and even antimetastatic activity in vitro and in vivo.

Keywords

ligandi;imunoterapevtiki;NOD1 agonisti;NOD1 antagonisti;NOD2 agonisti;NOD2 antagonisti;adjuvants;cancer immunotherapy;immunotherapeutics;NOD1agonists;NOD1 antagonists;NOD2 agonists;NOD2 antagonists;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL FFA - Faculty of Pharmacy
Publisher: Wiley
UDC: 615.4:54
COBISS: 4641905 Link will open in a new window
ISSN: 1098-1128
Views: 319
Downloads: 145
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: Farmacevtska kemija;Imunoterapija;
Type (COBISS): Article
Embargo end date (OpenAIRE): 2019-12-13
Pages: str. 1447-1484
Volume: ǂVol. ǂ39
Issue: ǂiss. ǂ5
Chronology: 2019
DOI: 10.1002/med.21557
ID: 12639655